Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01740154 · ClinicalTrials.gov registry record · NA
Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
A NA study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT01740154: Clinical Trial NA study, sponsored by Case Comprehensive Cancer Center.
NCT01740154 is a NA study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01740154, a NA study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine how sunitinib (sunitinib malate) causes fatigue. Patients will be asked to complete a brief questionnaire (survey) to rate their levels of fatigue every two weeks while they are participating in this research study. The questionnaire takes approximately 10-15 minutes to complete and is 9 questions. A series of physical measurements for fatigue will be performed before the first dose of sunitinib and again (4) weeks later to see if there are any changes in physical level of fatigues
Primary Outcome
The MTF will be elicited by supramaximal-intensity electrical stimulation of the muscle before and after the sustained contraction (SC). If the muscle is fatigued at the end of the SC, the MTF will be reduced because the ability of muscle to generate force declines with fatigue. If the sunitinib treatment results in minimal muscular fatigue, the MTF will not have as much reduction in the 2nd as that in the 1st session.
Interventions
- OTHER survey administration
- PROCEDURE transcranial magnetic stimulation
- DRUG sunitinib malate
- PROCEDURE electromyography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-03 |
| Phase | NA |
Why NCT01740154 stopped before completion
NCT01740154 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which survey administration is the first listed.
NCT01740154 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01740154 about?
NCT01740154 is a clinical study titled "Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer". The purpose of this research study is to determine how sunitinib (sunitinib malate) causes fatigue. Patients will be asked to complete a brief questionnaire (survey) to rate their levels of fatigue every two weeks while they are participating in this research study. The questionnaire takes approxima...
What is the current status of trial NCT01740154?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2012-09. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01740154?
The interventions under investigation include: survey administration (OTHER), transcranial magnetic stimulation (PROCEDURE), sunitinib malate (DRUG), electromyography (PROCEDURE).
Who is sponsoring clinical trial NCT01740154?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01740154's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia